Johnson & Johnson’s (JNJ) Multiple Myeloma Breakthrough Drives Buy Rating From Guggenheim

Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim reaffirmed a Buy rating and $206 price target on healthcare giant Johnson & Johnson (NYSE:JNJ), citing favorable clinical trial findings for its multiple myeloma therapy. The firm noted preliminary data from the MajesTEC-3 trial, which combines Johnson & Johnson (NYSE:JNJ)’s Tecvayli and Darzalex medications, as “overwhelmingly positive” and potentially creating a novel standard of treatment for relapsed/refractory multiple myeloma patients.

Pixabay/Public Domain

In comparison to current therapy standard’s, the Tecvayli-Darzalex combination considerably enhanced both progression-free survival and overall survival. Previous Phase 2 data also demonstrated encouraging outcomes, with all evaluable patients achieving a 100% overall response rate with little residual disease negativity.

Guggenheim believes that the data presentation at the upcoming annual American Society of Hematology Meeting in December will highlight a “paradigm shift” in multiple myeloma treatment, potentially boosting Tecvayli’s market share.

Johnson & Johnson (NYSE:JNJ) is a diversified healthcare company. It operates through three main segments: Innovative Medicine, MedTech, and Consumer Health. Its products range from pharmaceuticals and medical devices to widely recognized consumer brands.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.